Have a feature idea you'd love to see implemented?
Let us know!
BPMC Blueprint Medicines Corp
Price (delayed)
$83.09
Market cap
$5.26B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.37
Enterprise value
$5.67B
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company
Highlights
BPMC's gross profit has surged by 68% year-on-year and by 28% since the previous quarter
Blueprint Medicines's EPS has surged by 63% YoY and by 29% QoQ
BPMC's debt has soared by 99% year-on-year and by 44% since the previous quarter
BPMC's quick ratio is down by 22% year-on-year
Key stats
What are the main financial stats of BPMC
Market
Valuations
Earnings
Shares outstanding
63.35M
Market cap
$5.26B
Enterprise value
$5.67B
Price to earnings (P/E)
N/A
Price to book (P/B)
16.25
Price to sales (P/S)
14.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.64
Revenue
$362.8M
EBIT
-$183.21M
EBITDA
-$160.87M
Free cash flow
-$347.59M
Per share
Balance sheet
Liquidity
EPS
-$3.37
Free cash flow per share
-$5.53
Book value per share
$5.11
Revenue per share
$5.77
TBVPS
$19.15
Total assets
$1.2B
Total liabilities
$883.32M
Debt
$474.82M
Equity
$320.24M
Working capital
$659.74M
Debt to equity
1.48
Current ratio
3.71
Quick ratio
3.52
Net debt/EBITDA
-2.55
Margins
Efficiency
Dividend
EBITDA margin
-44.3%
Gross margin
95.7%
Net margin
-56.6%
Operating margin
-98.1%
Return on assets
-18.7%
Return on equity
-85.3%
Return on invested capital
-15.7%
Return on capital employed
-19.1%
Return on sales
-50.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BPMC stock price
How has the Blueprint Medicines stock price performed over time
Intraday
-1.55%
1 week
-3.38%
1 month
-7.95%
1 year
79.73%
YTD
-9.92%
QTD
-10.17%
Financial performance
How have Blueprint Medicines's revenue and profit performed over time
Revenue
$362.8M
Gross profit
$347.24M
Operating income
-$355.96M
Net income
-$205.49M
Gross margin
95.7%
Net margin
-56.6%
BPMC's net margin has soared by 77% year-on-year and by 45% since the previous quarter
BPMC's gross profit has surged by 68% year-on-year and by 28% since the previous quarter
The net income has soared by 63% YoY and by 29% QoQ
Blueprint Medicines's revenue has surged by 61% YoY and by 29% QoQ
Growth
What is Blueprint Medicines's growth rate over time
Valuation
What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
16.25
P/S
14.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.64
Blueprint Medicines's EPS has surged by 63% YoY and by 29% QoQ
The price to book (P/B) is 68% higher than the 5-year quarterly average of 9.7 but 33% lower than the last 4 quarters average of 24.4
Blueprint Medicines's equity has increased by 3.1% QoQ and by 2.9% YoY
Blueprint Medicines's revenue has surged by 61% YoY and by 29% QoQ
The P/S is 38% below the 5-year quarterly average of 23.1 and 24% below the last 4 quarters average of 19.0
Efficiency
How efficient is Blueprint Medicines business performance
Blueprint Medicines's return on sales has surged by 78% YoY and by 47% QoQ
The ROIC has soared by 65% YoY and by 36% from the previous quarter
The company's return on assets has surged by 57% YoY and by 30% QoQ
BPMC's return on equity is up by 29% since the previous quarter and by 28% year-on-year
Dividends
What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BPMC.
Financial health
How did Blueprint Medicines financials performed over time
BPMC's total assets is 36% greater than its total liabilities
Blueprint Medicines's current ratio has decreased by 23% YoY
BPMC's quick ratio is down by 22% year-on-year
BPMC's debt is 48% greater than its equity
BPMC's debt has soared by 99% year-on-year and by 44% since the previous quarter
BPMC's debt to equity has surged by 92% year-on-year and by 40% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.